CORPORATE PRESENTATION

genflowbiosciences

longer better life

# OTC.QB:GENFF

# LSE:GENF

# FORWARD LOOKING STATEMENT

This presentation contains express or implied information and statements that might be deemed forward-looking information and statements in respect of Genflow Biosciences. They do not constitute historical facts. These information and statements include financial projections that are based upon certain assumptions and assessments made by Genflow Biosciences' management in light of its experience and its perception of historical trends, current economic and industry conditions, expected future developments and other factors they believe to be appropriate. These forward-looking statements include statements typically using conditional and containing verbs such as "expect", "anticipate", "believe", "target", "plan", or "estimate", their declensions and conjugations and words of similar import. Although the Genflow Biosciences' management believes that the forward-looking statements and information are reasonable, the Genflow Biosciences' shareholders and other investors are cautioned that the completion of such expectations is by nature subject to various risks, known or not, and uncertainties which are difficult to predict and generally beyond the control of Genflow Biosciences. These risks could cause actual results and developments to differ materially from those expressed in or implied or projected by the forward-looking statements. These risks include those discussed or identified in the public filings made by Genflow Biosciences with the AMF. Such forward-looking statements are not guarantees of future performance. This presentation includes only summary information and should be read with the Genflow Biosciences Universal Registration Document filed with the AMF on 15 April 2022 including the 2021 Financial results, all available on the Genflow Biosciences' website. Other than as required by applicable law, Genflow Biosciences issues this presentation at the date hereof and does not undertake any obligation to update or revise the forward-looking information or statements. This presentation does not constitute an offer to sell the shares or soliciting an offer to purchase any of the Shares to any person in any jurisdiction where such an offer or solicitation is not permitted. The Shares may not be offered or sold, directly or indirectly, may be distributed or sent to any person or into any jurisdiction, except in circumstances that will result in the compliance with all applicable laws and regulations. Persons into whose possession this presentation may come are required to inform themselves about, and to observe all, such restrictions. The Company accept no responsibility for any violation by any person, whether or not it is a prospective purchaser of Shares, of any such restriction. The information contained in this presentation has not been independently verified and no commitment, representation or warranty, express or implied, is given by the Company or anyone of its directors, officers or respective affiliates or any other person and may not serve as the basis for the veracity, completeness, accuracy or completeness of the information contained in this document (or for any omission of any information in this presentation) or any other information relating to the Company or its affiliates. The information contained in this document is provided only as of the date of this document and may be subject to update, supplement, revision, verification and modification. They can be modified significantly. The Company is not subject to an obligation to update the information contained in this document and any opinion expressed in this document is subject to change without notice. The Company, its advisers, its representatives cannot be held responsible in any manner whatsoever for any loss of any nature whatsoever resulting from the use of this document or its contents or otherwise related in any way to this document. This document contains information relating to the Company's markets and the positioning of the Company in these markets. This information is derived from various sources and estimates of the Company. Investors cannot rely on this information to make their investment decision.

# SNAPSHOT

We seek to create a **healthier society** where anti-ageing interventions extend global healthspan and lifespan

## DISRUPTIVE ANTI-AGEING DRUG

- Developing transformative gene therapies targeting the upstream biology of ageing
- Centenarian variant SIRT6-based gene therapies with extensive preclinical data suggests extension of life and health span

## DIVERSIFIED PLAN

- The company is undertaking pre-clinical trials and expect first-in-human in the next 18 months
- The company intends to develop its lead compound for the treatment of Werner Syndrome (WS) patients (an accelerated ageing disease) and nonalcoholic steatohepatitis (NASH)

## EXPERIENCED TEAM

- Exceptional team with decades of experience in the pharmaceutical and health industries
- First rate academics from top universities and industry leaders



# SCIENTIFIC ADVISORY BOARD

**DR. ERIC VERDIN MD PHD**
CEO & President of

Buck
Live better longer.

Affiliated with

UCSF School of Medicine

**DR. VERA GORBUNOVA PHD**
Co-Director of

Community
University of Rochester
UR Aging Institute
Vital Discovery
Vital Care
Vital Living

Affiliated with

מכון ויצמן למדע
WEIZMANN INSTITUTE OF SCIENCE

**DR. MATTHEW HIRSCHEY PHD**
Assistant Professor at

Duke University
School of Medicine

Affiliated with

American Heart Association.

**DR. MANLIO VINCIGUERRA PHD**
Principal Investigator at

THE UNIVERSITY of LIVERPOOL

Affiliated with

UCL

genflowbiosciences
longer better life

**OTC.QB:GENFF LSE:GENF**

# BOARD OF DIRECTORS

**Mrs TAMARA JOSEPH**

Independent Non-Executive Chair

- Seasoned health care leader with extensive experience in both early-stage and commercial biotech companies
- Supported Nasdaq financings of over $800m
- Currently serving as Chief Legal Officer at Nasdaq-listed Spero Therapeutics Inc.
- served as an adviser to the boards of five US publicly traded biotechs, including Cubist Pharmaceuticals Inc.
- BA in Economics from Duke, a JD from the University of Michigan, and LLM degrees from Belgium and the University of Paris

**DR ERIC LEIRE MD MBA**

Founder & CEO

- MD and MBA, Eric has been involved in biotech for over 30 years
- Held senior positions including CEO of publicly traded biotech companies (Nasdaq, OTC.QB, OMX.Nasdaq)
- Inventor of several patents and authors of medical peer-reviewed publications

# BOARD OF DIRECTORS

**DR. YASSINE BENDIABDALLAH**
Independent
Non-Executive Director

- M Pharm, PhD, IP
- Functional Medicine Specialist
- Anticancer research scientist at the Cancer Research UK at University College London
- Various distinctions and publications in peer-reviewed academic journals

**DR. CHARLES FANNEAU DE LA HORIE**
Independent
Non-Executive Director

- Served as Chief Executive Officer at three biotech companies, including Euronext Growth traded, Pherecydes Pharma; and Neovacs, a therapeutic vaccine company.
- Held senior positions at Biogen, a Nasdaq listed global biotechnology company both in Europe and in the USA including management of a $700m sales force in the USA
- Graduate of the National Veterinary School of Lyon (1982) and an MBA from INSEAD (1988)

**DR. PETER KING LEWIS**
Independent
Non-Executive Director

- Seaman Officer and Diver in Royal Navy
- Studied medicine at St Bartholomew's Hospital, London
- Founder of KLFP Ltd and OfficeGP Ltd
- Past President of Independent Doctors Federation and Chelsea Clinical Society

# ABOUT GENFLOW BIOSCIENCES

Genflow Biosciences Plc is a UK based biotech company with R&D facilities in Belgium and an office in Cambridge, MA, driven by one mission: **to deliver medicines that potentially halt, slow, or reverse the ageing process in humans and dogs.**

Genflow is listed on the London Stock Market (**GENF.L**) and is trading on OTC.QB (GENFF)

Genflow's lead compound, GF-1002, works through a **centenarian variant** (a variant gene found in people living to 100 years or more) of the **SIRT6 gene** and has yielded promising preclinical results.

Managed by an experienced team with decades of experience in the pharmaceutical and biotech industries, the company is optimistic that development programs will continue **at pace in the next 24 months**.

genflowbiosciences
longer better life

# AGEING

Age related diseases are the biggest health burden we face

Genflow treats ageing as the underlying risk factor for these diseases

Given the key role of genes in determining how we age Genflow focuses on gene therapeutics

2 years

life expectancy



10-13 years

life expectancy



88 years*

life expectancy

*expected LE in relation to baby boys born in the UK in 2018

Source: Morgan AE, Davies TJ, Mc Auley MT. The role of DNA methylation in ageing and cancer. Proc Nutr Soc. 2018 Nov;77(4):412-422. doi: 10.1017/S0029665118000150. Epub 2018 Apr 30. PMID: 29708096

# SIRT6 – REPAIRING DNA

SIRT6 gene/protein repairs DNA damage (especially double strand breaks (DSB)) and prevents senescence of our cells

- SIRT6 gene codes for SIRT6 protein
- Stronger SIRT6: Longer lifespan
- DSB repair coevolves with maximum lifespan (MLS) in rodents
- The activity of SIRT6 in stimulating DSB repair coevolves with MLS in rodents
- 5 amino acids determine the differential activities of mouse and beaver SIRT6





Source: Tian et al., 2019, Cell 177, 622–638 April 18, 2019

genflowbiosciences
longer better life

OTC.QB:GENFF LSE:GENF

# GENE REGULATION IN AGEING

Ageing is a function of overworked epigenetic regulator genes unable to respond to cellular DNA damage.

Many genes regulate ageing: we are focusing on the SIRT6 gene.

**Sirtuin 6 Gene (SIRT6)**

genflowbiosciences

Ageing is driven by 9 interlinked Hallmarks, all rooted in DNA damage. Targeting one individual factor is unlikely to be effective.





Sources:
R. White. J. Vijg. Do DNA DSB drive Ageing? Molecular Cell 63, September 1, 2016
Mao, Z et al SIRT6 promotes DNA repair under stress by activating PARP1. Science 332, 2011,1443-1446
F. Wang, CH Chan, K. Chen, et al. Deacetylation of FOXO3 by SIRT1 or SIRT2 leads to Skp2-mediated FOXO3 ubiquitination and degradation. Oncogenes 31, no. 12. March 2012: 1546-57

# FOCUS ON CENTENARIAN SIRT6

SIRT6 centenarian variant gene has more efficient DNA repair properties

Homologous Recombination Repair




Non Homologous End Joining Repair




Relative PARP1 Ribosilation




genflowbiosciences
longer better life

OTC.QB:GENFF LSE:GENF

# DELIVERY SYSTEM: SAFE AND COST-EFFECTIVE

The patent-pending technology has already been tested in several preclinical studies

**01**

Non-integrating, no risk of insertional oncogenesis

**02**

Non-replicating, safe transient expression

**03**

Reduced potential for immunogenicity

genflowbiosciences
longer better life

# ADVANTAGES OF EXOSOME BASED DELIVERY

Exo-AAV can mediate efficient, specific,  and more durable SIRT6 expression in liver compared to conventional AAV

**No Immunogenicity**

Lack of local and systemic immunogenicity

**Potency Advantage**

Improved transduction versus free AAVs
Rapid uptake and sustained



**Targeted Delivery**

Engineered exosome to direct to specific cell types

**Therapeutic Window**

Potency improvement.
Local retention.
Lack of systemic leakage

Efficient loading of AAVs into the exosome lumen

genflowbiosciences
longer better life

Hudry E, Martin C, Gandhi S, György B, Scheffer DI, Mu D, Merkel SF, Mingozzi F, Fitzpatrick Z, Dimant H, Masek M, Ragan T, Tan S, Brisson AR, Ramirez SH, Hyman BT, Maguire CA. Exosome-associated AAV vector as a robust and convenient neuroscience tool. Gene Ther. 2016 Apr;23(4):380-92. doi: 10.1038/gt.2016.11. Epub 2016 Feb 2. Erratum in: Gene Ther. 2016 Nov;23 (11):819. PMID: 26836117; PMCID: PMC4824662.

# PRODUCT PIPELINE

Pipeline status

Basic Research » Development » IND Enabling » Human Clinical Trials

| | | |
|---|---|---|
| Human | **GF-1002** –Suspension of AAV, expressing cDNA of centenarian variant of SIRT6 in fibroblasts | Phase I/II Werner Syndrome |
| Human | **GF-1003** –Exo-AAV vector for intravenous infusion, expressing cDNA of centenarian variant of SIRT6 in liver | Phase I/II NASH |
| Human | **GF-1005** Sarcopenia Mitochondrial disfunction | Phase I Sarcopenia |
| Animal | **GF-1004** –Suspension of AAV vector for intravenous infusion, obtaining cDNA of centenarian variant of SIRT6 | Pivotal trial anti-ageing for dogs with vet partner |

Collaborations

genflowbiosciences
longer better life

**OTC.QB:GENFF LSE:GENF**

# LONGEVITY LANDSCAPE

| COMPANY | OVERVIEW | TECHNOLOGY | FOCUSED ON | LOCATION |
|---|---|---|---|---|
| UNITY BIOTECHNOLOGY | Clinical stage, Phase 2<br>Nasdaq (UBX) Mkt Cap $785M | Small molecules senolytic | Senescence | USA, San Francisco, CA |
| AGEX THERAPEUTICS | Pre-clinical stage<br>NYSE (AGE), Mkt Cap $25M | Therapeutics that seek to address human aging | Stem cells | USA, Almeda, CA |
| verve THERAPEUTICS | Clinical stage, Phase 1<br>Nasdaq (VERV) Mkt Cap $885 M | In Vivo LNP CRIPR gene editing | Hypercholesterolemia | USA, Cambridge, MA |
| FREQUENCY THERAPEUTICS | Pre-clinical stage<br>Nasdaq (FREQ) Market Cap $16 M | Small molecules to activate progenitor cells for MS | Stem cell exhaustion | USA, Woburn, MA |
| life BIOSCIENCES | Pre-clinical stage<br>Private, raised $124 M | Epigenetic reprogramming | Mitochondrial dysfunction | USA, Boston, MA |
| biosplice | Clinical stage, Phase 3<br>Private, raised $778M | Alternative splicing modulation to develop medicines to treat ageing-related diseases | Osteoarthritis | USA, San Diego, CA |
| REJUVENATE BIO | Clinical stage, Phase 1<br>Private, raised $26M | Gene therapy | Proteostatis | USA, San Carlos, CA |

# NASH PROGRAM




## Adipogenesis







## Fibrosis




## Tumorigenicity




- Affecting estimated 35 million people globally
  - Increasing prevalence
  - Leading cause of chronic liver disease and liver transplant
- Significant unmet medical need with no approved therapies
- Clear regulatory accelerated development pathway. EMA and FDA guidelines accept:
  - Key surrogate outcomes for therapeutic trials: regression of fibrosis or resolution of NASH
  - These histological changes are achievable within a 12-18-month time-frame
  - Placebo control
  - Conditional fast track approval

*Pais R, Barritt AS 4th, Calmus Y, Scatton O, Runge T, Lebray P, Poynard T, Ratziu V, Conti F. NAFLD and liver transplantation: Current burden and expected challenges. J Hepatol. 2016 Dec;65(6):1245-1257.*
*Vlad Ratziu, Sven Francque, Arun Sanyal, Breakthroughs in therapies for NASH and remaining challenges, Journal of Hepatology, Volume 76, Issue 6, 2022*

# INVESTMENT HIGHLIGHTS

| | |
|---|---|
| **Large Market Opportunity** | NASH 35 Million globally. Increasing prevalence.<br>Door opener to even broader anti-aging indication |
| **Long Life IP** | 2 patent family SIRT6 centenarian and gene delivery<br>Additional upcoming patent applications |
| **Compelling product** | Proprietary innovative gene delivery system: exo-AAV<br>Centenarian variant of SIRT6 gene |
| **Multiple upcoming catalysts** | Multiple key clinical and regulatory milestones expected in next 18 months<br>Undervalued stock opportunity<br>Potential acquisition by pharmaceutical partner |

genflowbiosciences

longer better life

Genflow Biosciences Plc 15
Ingestre Place London, UK
W1F 0DU

Genflow Biosciences SRL
Biopark Gosselies
48 rue Auguste Piccard 6041
Gosselies, Belgium

Genflow Biosciences Inc
Harvard Square
18 Brattle Street, Suite 400
Cambridge, MA 02138, US

www.genflowbio.com

# RATIONALE FOR NASH

SIRT6 may be a potential therapeutic target for liver fibrosis




OTC.QB:GENFF LSE:GENF

# VETERINARY PROGRAM

Genflow is developing the same delivery system for dogs. This has several advantages.

Dogs must be used as part of development for the human program

Short-term possibility for out-licensing following completion of the preclinical studies in dogs

Results will be obtained at no extra cost to the main program

Owners are interested in prolonged health and life extension for their pets

Demand is adequate to justify a separate program

The regulatory hurdle is much lower than for the human program

genflowbiosciences
longer better life

# INTELLECTUAL PROPERTY

| | | |
|---|---|---|
| EFS ID | 1-21069 | 43268050 |
| Application Number | US 63/188,573 | US 63/222,557 |
| Title of Invention | Variants of SIRT6 for use in preventing and/or treating age-related diseases | Method of in vivo administration of the coding sequence of the SIRT6 gene via Adeno-Associated-Virus |
| First Named Inventor | Vera Gorbunova, Seluanov and Suh | Eric Leire |
| Receipt Date | May 14, 2021 | July 16, 2021 |
| Ownership | Worldwide Exclusive license from University Rochester New York / Columbia University / Albert Einstein College of medicine | Genflow Biosciences SRL |

Applications are being made to the USPTO to patent Genflow's proprietary technology.

# Project cash burn over the 36m project life (inc. grant income)






| BUDGET (K€) | H2/23 | 2024 | 2025 | Sum |
|---|---|---|---|---|
| Preclin | 170 | 300 | 600 | 1.070 |
| CMC | | 1.550 | 1.500 | 3.050 |
| Regul. & Clinical | 10 | 320 | 2.650 | 2.980 |
| **Total I** | 460 | 2.120 | 4.500 | 7.100 |
| Mgmt | 170 | 450 | 510 | 1.130 |
| R&D | 150 | 500 | 500 | 1.650 |
| SGA | 72 | 150 | 170 | 392 |
| **Total II** | 852 | 3.220 | 5.680 | 10.272 |

<u>Achieved Milestones to support Fundraising</u>

- Regulatory de-risked in US: pre-IND
- Preclinically de-risked: In vivo proof of concept & confirmed dose for NASH
- Tech transfer completed and ready to kick off GMP

<u>Fundraising story line</u>

**Advanced preclinical stage: “IND within 12 months aiming for clinical efficacy PoC NASH in Q4-26”**

<u>Risk</u>

Negative / non-favorable FDA feedback would be clear showstopper of project